Rekrutierende Studie = ; Fortlaufende Studie = ; Förderung durch ein IRDiRC-Mitglied = ; ERN-Mitglied =

Nationale klinische Studie(n)

BELGIEN

ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE

CREATE (EORTC-90101): Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumor induced by causal alterations of ALK and/or MET - BE

Institution: Information not provided - BE

Mehr Details

ESTLAND

Tartu
TARTU

Phase III study to evaluate GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma

Haematology and Oncology Clinic - Tartu University Hospital

Haematology and Oncology Clinic

Mehr Details

VEREINIGTES KONIGREICH

Greater London
LONDON

CREATE (EORTC 90101): Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumours induced by causal alterations of either ALK or MET - UK

UCLH NHS Foundation Trust - University College Hospital

The London Sarcoma Service

Mehr Details